Abstract:Neuroimaging biomarkers can detect disease pre-clinically but their prognostic value, alone or in combination, is uncertain. Volumetric MRI and FDG-PET data were compared in 18 cognitively unimpaired participants approximately 2 years (1.8±0.8) before the clinical diagnosis of aMCI due to AD and 35 participants matched for age and sex who remained unimpaired for ≥4 years (nonprogressors) after their imaging acquisition. We further compared the 18 progressors to 20 nonprogresors matched for age, sex, and APOE status. Participants were followed in the Arizona APOE Cohort, have a reported first degree family history of possible AD dementia, and were enriched for APOE4 gene dose. Voxel-wise analyses were used to characterize reductions in regional gray matter volume and cerebral glucose metabolism between groups. Binary logistic regression, leave-one-out, and Receiver Operating Curve analyses were performed to characterize the extent to which posterior cingulate glucose metabolism, the AD-related hypometabolic conversion index (HCI), hippocampal volumes (HCV), and entorhinal cortical thickness, alone or in combination, could distinguish between subsequent progressors and non-progressors. The progressor and non-progressor groups did not differ significantly in their age (68±4), sex, education, or general intelligence. The progressor group had significantly more APOEe4 carriers than the group that was not matched for APOE. Compared to both nonprogressor groups, those who developed aMCI in approximately 2 years had significant (FWE corrected p ≤ 0.05) decreases in glucose metabolism, gray matter volume, and cortical thickness in regions known to be preferentially affected by AD. The best predictor of aMCI when matched for APOE was right and left HCV at 79% sensitivity and 78% specificity, with no improvement in performance when adding FDG-PET data. The best predictor for the groups not balanced for APOE was left HCV at 74% sensitivity and 72% specificity; combining MRI and FDG PET data increased the sensitivity and specificity to 77% and 78%. Based on logistic regression models, APOE e4 partially mediated the effect on the left hippocampus. This study supports the possibility that regional MRI and FDG PET measurements, individually or in combination, could help predict the likelihood of progressing to the clinical stages of AD.

MRI-Driven Longitudinal Studies of Hippocampal Alterations During the Initial Cognitive Decline

Distinct Atrophy Pattern of Hippocampal Subfields in Patients with Progressive and Stable Mild Cognitive Impairment: A Longitudinal MRI Study

Altered Functional Connectivity Pattern of Hippocampal Subfields in Individuals with Objectively-Defined Subtle Cognitive Decline and Its Association with Cognition and Cerebrospinal Fluid Biomarkers

Analysis of Hippocampus Evolution Patterns and Prediction of Conversion in Mild Cognitive Impairment Using Multivariate Morphometry Statistics.

Morphometric Analysis of Hippocampus and Lateral Ventricle Reveals Regional Difference Between Cognitively Stable and Declining Persons

Trajectories of the Hippocampal Subfields Atrophy in the Alzheimer's Disease: A Structural Imaging Study.

Improved Prediction of Imminent Progression to Clinically Significant Memory Decline Using Surface Multivariate Morphometry Statistics and Sparse Coding

Can Multi-Modal Neuroimaging Evidence from Hippocampus Provide Biomarkers for the Progression of Amnestic Mild Cognitive Impairment?

Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET.

Longitudinal Structural MRI Study in Process of Mild Cognitive Impairment Converting to AD Dementia

Machine Learning-Derived MRI-Based Neurodegeneration Biomarker for Alzheimer's Disease: A Multi-Database Validation Study

Progressive Volume Atrophy in Hippocampal Subfields and the Correlation with Cognition in Alzheimer’s Disease and Mild Cognitive Impairment

Aberrant Hippocampal Subregion Networks Associated with the Classifications of Amci Subjects: A Longitudinal Resting-State Study

MR-based Spatiotemporal Anisotropic Atrophy Evaluation of Hippocampus in Alzheimer's Disease Progression by Multiscale Skeletal Representation.

Cognitive Function Assessment and Prediction for Subjective Cognitive Decline and Mild Cognitive Impairment.

Progression of hippocampal subfield atrophy and asymmetry in Alzheimer's disease

IC‐P‐089: Can Three Months MRI Volumetric Parameters Help the Prediction of Progression from MCI to Alzheimer's Disease? Results from the Addneuromed Study

Radiomic Features of Hippocampal Subregions in Alzheimer’s Disease and Amnestic Mild Cognitive Impairment

P1‐325: Predicting Progression to Mild Cognitive Impairment in Cognitively Unimpaired Individuals Using Neuroimaging Biomarkers

Longitudinal Structural MRI Analysis and Classification in Alzheimer's Disease and Mild Cognitive Impairment.

Combined cognitive assessment and automated MRI volumetry improves the diagnostic accuracy of detecting MCI due to Alzheimer's disease